Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.

Eneida Turiján-EspinozaVíctor Manuel Ruíz-RodríguezEdith Elena Uresti-RiveraErnesto Martínez-LeijaJosé de Jesús Zermeño-NavaArturo Guel-PañolaSilvia Romano-MorenoJuan Manuel Vargas-MoralesDiana Patricia Portales-Pérez

Published in: Cancer chemotherapy and pharmacology (2021)

The early clinical response and its association with SNPs in the ABCB1 transporter are preserved until the pathological response to neoadjuvant chemotherapy; therefore, it could be used as a predictor of chemoresistance in locally advanced breast cancer patients of the Mexican population.

Keyphrases

neoadjuvant chemotherapy
locally advanced
rectal cancer
squamous cell carcinoma
genome wide
radiation therapy
sentinel lymph node
phase ii study
high throughput
mesenchymal stem cells
dna methylation
early stage
bone marrow
cancer stem cells
single cell